Clinical effect of propofol combined with Remimazolam tosylate intravenous anesthesia on patients undergoing gastric cancer surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043993

Enrollment

Unknown

Registered

2021-03-06

Start date

2021-03-01

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Control group:Propofol

Test group1:Propofol combined with low-dose Remimazolam tosylate

Test group2:Propofol combined with middle-dose Remimazolam tosylate

Test group3:Propofol combined with high-dose Remimazolam tosylate

Eligibility

Sex/Gender

All

Age

60 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic radical gastric cancer surgery; 2. Patients aged 60-70 years; 3. Patients with BMI18.5-24kg/m2; 4. Patients with ASA I~III; 5. Patients who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic or contraindicated to experimental drugs and auxiliary drugs; 2. Patients deemed unsuitable to participate in the study by the researcher.

Design outcomes

Primary

Measure	Time frame
Cardiac output, CO;Small vessel resistance, SVR;	—

Secondary

Measure	Time frame
Vasoactive drugs;Spontaneous breathing recovery time;Time to meet extubation indications;Fully awake time;	—

Countries

China

Contacts

Public ContactLu Jing

Linyi People's Hospital

lujing_xinlang@sina.com+86 17661666379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026